Published in Clinical Oncology Week, November 27th, 2006
The results exhibited that this colorimetric version of Biocurex's RECAF test detected more than twice the amount of cancers than the most widely used cancer detection test utilized - the PSA test.
Biocurex previously obtained excellent results with a radio-immunoassay format. An immunoassay takes advantage of the exquisite specificity of an antibody to detect one and only one substance - in our case RECAF -...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.